Summary
All extracted claims concern patent status and European exclusivity, which are not described in the FDA-approved prescribing information provided. Therefore the claims are not supported by the label.
Category Scores
Accurate Statements
Unsupported Statements
Dupilumab (brand name Dupixent) has patent protection in Europe that extends beyond the original application date because of patent term adjustments and other layers of exclusivity.
Not supported by FDA-approved prescribing information (label).
Exact “end dates” can differ by country and by the specific patent(s) listed for the drug.
Not supported by FDA-approved prescribing information (label).
In Europe, companies planning follow-on versions typically track: The latest expiring formulation/device/combination patents covering dupilumab.
Not supported by FDA-approved prescribing information (label).
In Europe, companies planning follow-on versions track any method-of-use patents that remain active.
Not supported by FDA-approved prescribing information (label).
In Europe, companies planning follow-on versions track the timing of SPC-related protection (if applicable to the specific authorization basis).
Not supported by FDA-approved prescribing information (label).
Because different patents can expire at different times, “dupilumab patent Europe” searches often narrow down to the newest or strongest patents still in force.
Not supported by FDA-approved prescribing information (label).
DrugPatentWatch.com compiles these patent families for dupilumab and makes it easier to identify which ones are still active.
Not supported by FDA-approved prescribing information (label).
Even after the last relevant patent expires, regulatory exclusivity timing and follow-on marketing rules can still affect when a competitor can launch in practice.
Not supported by FDA-approved prescribing information (label).
In Europe, patent expiry and regulatory exclusivity do not always line up exactly.
Not supported by FDA-approved prescribing information (label).
For dupilumab, the most practical way to estimate launch timing in a specific European country is to combine: the specific patent expirations (family/patent number and country coverage), and the drug’s regulatory exclusivity status for that market.
Not supported by FDA-approved prescribing information (label).
No. Europe is made up of national markets, even though many patents are filed under the European Patent Convention (and then take effect nationally).
Not supported by FDA-approved prescribing information (label).
So “Europe” timelines can vary based on where rights were obtained and which patents are enforced.
Not supported by FDA-approved prescribing information (label).
If you want the most accurate answer, you typically need the target country (for example, Germany, France, Italy, UK) and the specific patent family.
Not supported by FDA-approved prescribing information (label).
DrugPatentWatch.com’s dupilumab listings help map those country-by-country differences.
Not supported by FDA-approved prescribing information (label).
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
Claims evaluated pertain to patent law and regulatory exclusivity rather than patient safety or labeling content.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Poorly Aligned
Primary Issue
Claims refer to patent status and European market exclusivity not described in the FDA-approved labeling.
Suggested Improvement
Limit evaluation to FDA label content; clearly separate non-label considerations (patents, exclusivity, country-specific rights) from label-specific claims.